File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: Randomised, double-blind, controlled study
  • Basic View
  • Metadata View
  • XML View
TitleSafety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: Randomised, double-blind, controlled study
 
AuthorsPhua, KB1
Lim, FS3
Lau, YL2
Nelson, EAS8
Huang, LM5
Quak, SH6
Lee, BW7
Teoh, YL3 4
Tang, H4
Boudville, I4
Oostvogels, LC4
Suryakiran, PV4
Smolenov, IV4
Han, HH4
Bock, HL4
 
Issue Date2009
 
PublisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
 
CitationVaccine, 2009, v. 27 n. 43, p. 5936-5941 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.vaccine.2009.07.098
 
AbstractThis study evaluates the safety and efficacy against severe rotavirus gastroenteritis of the oral live attenuated human rotavirus vaccine RIX4414 (Rotarix™) during the first 2 years of life in Asian infants from high-income countries. Healthy infants were enrolled to receive 2 doses of RIX4414 (N = 5359) or placebo (N = 5349). From 2 weeks post-dose 2 to 2 years of age, vaccine efficacy was 96.1% (95%CI:85.1%; 99.5%) against severe rotavirus gastroenteritis, 100% (95%CI:80.8%; 100%) against wild-type G1P[8] and 93.6% (95%CI:74.7%; 99.3%) against circulating non-G1 rotavirus types. No intussusception cases were reported within 31 days post-vaccination. RIX4414 shows a good safety profile and offers high protection during the first 2 years of life with potentially significant public health impact in this population. © 2009 Elsevier Ltd. All rights reserved.
 
ISSN0264-410X
2013 Impact Factor: 3.485
 
DOIhttp://dx.doi.org/10.1016/j.vaccine.2009.07.098
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorPhua, KB
 
dc.contributor.authorLim, FS
 
dc.contributor.authorLau, YL
 
dc.contributor.authorNelson, EAS
 
dc.contributor.authorHuang, LM
 
dc.contributor.authorQuak, SH
 
dc.contributor.authorLee, BW
 
dc.contributor.authorTeoh, YL
 
dc.contributor.authorTang, H
 
dc.contributor.authorBoudville, I
 
dc.contributor.authorOostvogels, LC
 
dc.contributor.authorSuryakiran, PV
 
dc.contributor.authorSmolenov, IV
 
dc.contributor.authorHan, HH
 
dc.contributor.authorBock, HL
 
dc.date.accessioned2012-10-30T06:08:26Z
 
dc.date.available2012-10-30T06:08:26Z
 
dc.date.issued2009
 
dc.description.abstractThis study evaluates the safety and efficacy against severe rotavirus gastroenteritis of the oral live attenuated human rotavirus vaccine RIX4414 (Rotarix™) during the first 2 years of life in Asian infants from high-income countries. Healthy infants were enrolled to receive 2 doses of RIX4414 (N = 5359) or placebo (N = 5349). From 2 weeks post-dose 2 to 2 years of age, vaccine efficacy was 96.1% (95%CI:85.1%; 99.5%) against severe rotavirus gastroenteritis, 100% (95%CI:80.8%; 100%) against wild-type G1P[8] and 93.6% (95%CI:74.7%; 99.3%) against circulating non-G1 rotavirus types. No intussusception cases were reported within 31 days post-vaccination. RIX4414 shows a good safety profile and offers high protection during the first 2 years of life with potentially significant public health impact in this population. © 2009 Elsevier Ltd. All rights reserved.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.identifier.citationVaccine, 2009, v. 27 n. 43, p. 5936-5941 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.vaccine.2009.07.098
 
dc.identifier.citeulike5432708
 
dc.identifier.doihttp://dx.doi.org/10.1016/j.vaccine.2009.07.098
 
dc.identifier.epage5941
 
dc.identifier.issn0264-410X
2013 Impact Factor: 3.485
 
dc.identifier.issue43
 
dc.identifier.pmid19679216
 
dc.identifier.scopuseid_2-s2.0-70349431081
 
dc.identifier.spage5936
 
dc.identifier.urihttp://hdl.handle.net/10722/170422
 
dc.identifier.volume27
 
dc.languageeng
 
dc.publisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
 
dc.publisher.placeUnited Kingdom
 
dc.relation.ispartofVaccine
 
dc.relation.referencesReferences in Scopus
 
dc.subject.meshChild, Preschool
 
dc.subject.meshDouble-Blind Method
 
dc.subject.meshGastroenteritis - Prevention & Control - Virology
 
dc.subject.meshHumans
 
dc.subject.meshInfant
 
dc.subject.meshRotavirus Infections - Prevention & Control
 
dc.subject.meshRotavirus Vaccines - Administration & Dosage
 
dc.subject.meshVaccines, Attenuated - Administration & Dosage
 
dc.titleSafety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: Randomised, double-blind, controlled study
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Phua, KB</contributor.author>
<contributor.author>Lim, FS</contributor.author>
<contributor.author>Lau, YL</contributor.author>
<contributor.author>Nelson, EAS</contributor.author>
<contributor.author>Huang, LM</contributor.author>
<contributor.author>Quak, SH</contributor.author>
<contributor.author>Lee, BW</contributor.author>
<contributor.author>Teoh, YL</contributor.author>
<contributor.author>Tang, H</contributor.author>
<contributor.author>Boudville, I</contributor.author>
<contributor.author>Oostvogels, LC</contributor.author>
<contributor.author>Suryakiran, PV</contributor.author>
<contributor.author>Smolenov, IV</contributor.author>
<contributor.author>Han, HH</contributor.author>
<contributor.author>Bock, HL</contributor.author>
<date.accessioned>2012-10-30T06:08:26Z</date.accessioned>
<date.available>2012-10-30T06:08:26Z</date.available>
<date.issued>2009</date.issued>
<identifier.citation>Vaccine, 2009, v. 27 n. 43, p. 5936-5941</identifier.citation>
<identifier.issn>0264-410X</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/170422</identifier.uri>
<description.abstract>This study evaluates the safety and efficacy against severe rotavirus gastroenteritis of the oral live attenuated human rotavirus vaccine RIX4414 (Rotarix&#8482;) during the first 2 years of life in Asian infants from high-income countries. Healthy infants were enrolled to receive 2 doses of RIX4414 (N = 5359) or placebo (N = 5349). From 2 weeks post-dose 2 to 2 years of age, vaccine efficacy was 96.1% (95%CI:85.1%; 99.5%) against severe rotavirus gastroenteritis, 100% (95%CI:80.8%; 100%) against wild-type G1P[8] and 93.6% (95%CI:74.7%; 99.3%) against circulating non-G1 rotavirus types. No intussusception cases were reported within 31 days post-vaccination. RIX4414 shows a good safety profile and offers high protection during the first 2 years of life with potentially significant public health impact in this population. &#169; 2009 Elsevier Ltd. All rights reserved.</description.abstract>
<language>eng</language>
<publisher>Elsevier Ltd. The Journal&apos;s web site is located at http://www.elsevier.com/locate/vaccine</publisher>
<relation.ispartof>Vaccine</relation.ispartof>
<subject.mesh>Child, Preschool</subject.mesh>
<subject.mesh>Double-Blind Method</subject.mesh>
<subject.mesh>Gastroenteritis - Prevention &amp; Control - Virology</subject.mesh>
<subject.mesh>Humans</subject.mesh>
<subject.mesh>Infant</subject.mesh>
<subject.mesh>Rotavirus Infections - Prevention &amp; Control</subject.mesh>
<subject.mesh>Rotavirus Vaccines - Administration &amp; Dosage</subject.mesh>
<subject.mesh>Vaccines, Attenuated - Administration &amp; Dosage</subject.mesh>
<title>Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: Randomised, double-blind, controlled study</title>
<type>Article</type>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1016/j.vaccine.2009.07.098</identifier.doi>
<identifier.pmid>19679216</identifier.pmid>
<identifier.scopus>eid_2-s2.0-70349431081</identifier.scopus>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-70349431081&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>27</identifier.volume>
<identifier.issue>43</identifier.issue>
<identifier.spage>5936</identifier.spage>
<identifier.epage>5941</identifier.epage>
<publisher.place>United Kingdom</publisher.place>
<identifier.citeulike>5432708</identifier.citeulike>
</item>
Author Affiliations
  1. KK Women's And Children's Hospital
  2. The University of Hong Kong
  3. National Healthcare Group Polyclinics, Singapore
  4. GlaxoSmithKline
  5. National Taiwan University Hospital
  6. National University of Singapore
  7. Mount Elizabeth Medical Centre
  8. Chinese University of Hong Kong